Cellectis (CLLS) Reiterated at Market Outperform by Citizens After MRD Clearance

April 14, 2026 5:05 AM

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $8.00 price target on Cellectis (NASDAQ: CLLS).The analyst commented, "CLLS ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found